Carvedilol treatment of chronic heart failure: A new era

Heart

Volumn 79, Issue SUPPL. 2, 1998, Pages

  Bristow, M R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; METOPROLOL; PROPRANOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC DISEASE; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VASODILATATION;

EID: 0031798377     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Bristow MR, Ginsburg R, Minobe WA, et al. Decreased catecholamine sensitvity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982:307-205-11.
2. Bristow MR, Kantrowitz NE, Ginsburg R, et al. β adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985;17(suppl 2):41-52.
3. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, et al. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95:169-75.
4. 1 receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
5. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986;8:1235-12.
6. Bristow MR, Anderson FL, Port JD, et al. Differences in βadrenergic neuroeffectpr mechanisms in ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-39.
7. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(suppl A):61A-71A.
8. 2-adrenergic receptor. Science 1994;264:562-6.
9. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpreesing the βARK inhibitor. Science 1995;268:1350-3.
10. 2-adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm 1989;35:295-303.
11. 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res 1989;64:474-81.
12. Bristow MR, Port JD, Gilbert EM. The role of receptor regulation in the treatment of heart failure. Cardiovasc Drugs Therapy 1989;3:971-8.
13. 1 receptor subtype in failing human left ventricular myocardium. Circulation 1997;95:1193-200.
14. 1 receptor mRNA abundance in the failing human heart. J Clin Invest 1993;92:2737-45.
15. Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am J Cardiol. [In press.]
16. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
17. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. EUr Heart J 1996;17(suppl B):8-16.
18. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992;19(suppl 1):S68-80.
19. Bristow MR, Minobe W, Rasmussen R, et al. β-adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. J Clin Invest 1992;89:803-15.
20. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
21. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
22. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
23. Hershberger RE, Wynn JR, Sundberg L, et al. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharm 1990;15:959-67.
24. Rimele TJ, Aarhus LL, Lorenz RR, et al. Pharmacology of bucindolol in isolated vascular smooth muscle. J Pharmacol Exp Therap 1984;231:317-25.
25. Gilbert EM, Anderson JL, Deitchman D, et at. Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
26. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-12.
27. Talwar KK, Bhargava B, Upasani PT, et al. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Cardiac Failure. [In press.]
28. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, LV functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation 1996;94:2817-25.
29. Bristow MR, Port JD. β-adrenergic blockade in chronic heart failure. Scand J Cardiol. [In press.]
30. Di Lenarda A, Gilbert EM, Olsen SL, et al. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991;17:142A.
31. Quaife RA, Gilbert EM, Christian PE, et al. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996;78:779-84.
32. Quaife RA, Christian PE, Gilbert EM, et al. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. [In press.]
33. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
34. Lowes BD, Gill EA, Rodriguez-Larrain J, et al. Carvedilol is associated with a reversal of remodeling in chronic heart failure. Circulation 1996;94(suppl 1):I-407.
35. Haber HL, Christopher LS, Gimple LW, et al. Why do patients with congestive hean failure tolerate the initiation of β-blocker therapy? Circulation 1993;88:1610-19.
36. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
37. Packer M, Bristow MR, Cohn JN, et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
38. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
39. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.